This article is a correction to:
Induction of RIPK3/MLKL-mediated necroptosis by Erigeron breviscapus injection exhibits potent antitumor effect
Xiuping Guo1
Rui Li1Jinjin Cui1Chujuan Hu1Haoyang Yu1Ling Ren1Yangyang Cheng1
Jiandong Jiang1*
Xiao Ding2*
Lulu Wang1*- 1Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
- 2State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China
A Corrigendum on
Induction of RIPK3/MLKL-mediated necroptosis by Erigeron breviscapus injection exhibits potent antitumor effect
by Guo X, Li R, Cui J, Hu C, Yu H, Ren L, Cheng Y, Jiang J, Ding X and Wang L (2023). Front. Pharmacol. 14:1219362. doi: 10.3389/fphar.2023.1219362
In the published article, there was an error in Figure 2 as published. The upper panels in Figures 2B, D were inadvertently misused during the final assembly of Figure 2. The corrected Figure 2 appear below.
FIGURE 2
FIGURE 2. EBI suppresses growth, migration, and invasion of SW620 cells. (A) SW620 cells were observed for morphologic changes at 12 h after EBI (10, 15, 20, 40, and 100 μg/mL) treatment. Scale bars indicate 50 μm. (B, C) The representative image (B) and quantitative analysis (C) of migrated cells after exposure to EBI (10, 15, 20, and 40 μg/mL, 24 h). Scale bars indicate 50 μm. (D, E) The representative image (D) and quantitative analysis (E) of invaded cells after exposure to EBI (10, 15, 20, and 40 μg/mL, 24 h). Scale bars indicate 50 μm. Mean ± SEM. ***p < 0.001, ****p < 0.0001 vs. EBI 0 μg/mL group (one-way ANOVA).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Erigeron breviscapus injection, Dengzhanxixin, Erigeron breviscapus (Vant.) Hand.-Mazz, colorectal cancer, necroptosis, drug resistance
Citation: Guo X, Li R, Cui J, Hu C, Yu H, Ren L, Cheng Y, Jiang J, Ding X and Wang L (2023) Corrigendum: Induction of RIPK3/MLKL-mediated necroptosis by Erigeron breviscapus injection exhibits potent antitumor effect. Front. Pharmacol. 14:1271953. doi: 10.3389/fphar.2023.1271953
Received: 03 August 2023; Accepted: 14 August 2023;
Published: 28 August 2023.
Edited and reviewed by:
Zhaohui Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, ChinaCopyright © 2023 Guo, Li, Cui, Hu, Yu, Ren, Cheng, Jiang, Ding and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jiandong Jiang, jiang.jdong@163.com; Xiao Ding, dingxiao@mail.kib.ac.cn; Lulu Wang, wanglulu@imb.cams.cn